Abstract:OBJECTIVE:(Background): Alzheimer's disease (AD), clinically characterized by the progressive neurodegenerative condition and cognitive impairment, is one of the main causes of disability in elder people worldwide. Recently, several animal studies indicated that the 'gut-brain' axis might contribute to the amyloid deposition of AD. However, data about gut dysbiosis in human AD remains scarce in the literature, especially including the whole process of AD. In this prospective and cross-sectional study, we aimed at identifying differences in microbiome between patients with AD (Pre-onset stage amnestic mild cognitive impairment, aMCI; and AD) and the normal cognition healthy controls (HC). Additionally, the potential association between IM and clinical characteristics of AD was evaluated.METHODS:A total of 97 subjects (33 AD, 32 aMCI, and 32 HC) were recruited in the study. The composition of gut bacterial communities was determined by 16S ribosomal RNA Miseq sequencing. In addition, Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt) was used to predict function shift of intestinal microbiota. The Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA) or Clinical Dementia Rating (CDR) scores were used to evaluate the severity of cognitive impairment in patients.RESULTS:The fecal microbial diversity was decreased in AD patients compared with aMCI patients and HC. And the microbial composition was distinct among aMCI, AD and healthy control groups. Among bacterial taxa, the proportion of phylum Firmicutes was significantly reduced (P = 0.008), whereas Proteobacteria (P = 0.024) was highly enriched in the AD compared with HC. In addition, similar alterations were observed at the order, class and family levels of these two phyla. And Gammaproteobacteria, Enterobacteriales and Enterobacteriaceae showed a progressive enriched prevalence from HC to aMCI and AD patients. Further, a significant correlation was observed between the clinical severity scores of AD patients and the abundance of altered microbiomes. Moreover, the KEGG results showed the increased modules related to glycan biosynthesis and metabolism in AD and aMCI patients and decreased pathways related to immune system in AD patients. Importantly, the discriminating models based on predominant microbiota could effectively distinguish aMCI and AD from HC (AUC = 0.890, 0.940, respectively), and also AD from aMCI (AUC = 0.925). Notably, the models based on the abundance of family Enterobacteriaceae could distinguish AD from both aMCI (AUC = 0.688) and HC (AUC = 0.698).CONCLUSIONS:Distinct microbial communities, especially enriched Enterobacteriaceae, were associated with patients with AD when compared with predementia stage aMCI and healthy subjects. These novel findings will give new clues to understand the disease and provide new therapeutic target for intervention or a marker for this disease.

Association of Peripheral Blood Cell Profile With Alzheimer's Disease: A Meta-Analysis

Peripheral Immune Cells Contribute to the Pathogenesis of Alzheimer's Disease

Cellular Transcriptional Alterations of Peripheral Blood in Alzheimer's Disease.

Association of peripheral immunity with cognition, neuroimaging, and Alzheimer’s pathology

Peripheral immune cell imbalance is associated with cortical beta-amyloid deposition and longitudinal cognitive decline

Exploring the links among peripheral immunity, biomarkers, cognition, and neuroimaging in Alzheimer's disease

Inflammatory Markers in Alzheimer’s Disease and Mild Cognitive Impairment: a Meta-Analysis and Systematic Review of 170 Studies

Characterization of peripheral immune cell populations in stable and progressive Alzheimer’s disease

Single-Cell RNA Sequencing of Peripheral Blood Reveals Immune Cell Signatures in Alzheimer’s Disease

Analysis of Immune Dysfunction and Predictors of Poor Prognosis in Patients with Alzheimer's Disease

Increased monocyte activity identified in Alzheimer’s disease by in depth single‐cell genomic and proteomic analysis

Altered Microbiomes Distinguish Alzheimer's Disease from Amnestic Mild Cognitive Impairment and Health in a Chinese Cohort.

Leukocyte Surface Biomarkers Implicate Deficits of Innate Immunity in Late‐onset Alzheimer’s Disease

Peripheral Immune Cells and Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease Pathology in Cognitively Intact Older Adults: the CABLE Study

Decreased Peripheral Brain-Derived Neurotrophic Factor Levels in Alzheimer's Disease: a Meta-Analysis Study (N=7277).

Changes of Aβ Antibody and Cytokines in Peripheral Blood from Patients with Alzheimer's Disease

Correlation between abnormal cellular immune and changes of magnetic resonance spectroscopy in patients with Alzheimer's disease

Meta-analysis and systematic review of peripheral platelet-associated biomarkers to explore the pathophysiology of alzheimer's disease

Peripheral immune profiles in individuals at genetic risk for amyotrophic lateral sclerosis and Alzheimer's disease

Integrating peripheral blood and brain transcriptomics to identify immunological features associated with Alzheimer's disease in mild cognitive impairment patients

Levels of IL-6 in Peripheral Blood and Cerebrospinal Fluid of Alzheimer's Disease: a Meta-Analysis